Stronger evidence for replication of NPPA using genome-wide genotyping data.
Stronger evidence for replication of NPPA using genome-wide genotyping data.
复制标题
使用全基因组基因分型数据提供 NPPA 复制的更有力证据。
DOI：
10.1164/ajrccm.181.1.96
复制
发表时间：
2010
影响因子：
24.7
通讯作者：
Weiss,ScottT
中科院分区：
文献类型：
--
作者：
Rogers,AngelaJ;Raby,BenjaminA;Lima,John;Lasky-Su,JessicaA;Murphy,Amy;Lazarus,Ross;Klanderman,Barbara;Sylvia,JodyS;Ziniti,JohnP;Lange,Christoph;Celedón,JuanC;Silverman,EdwinK;Weiss,ScottT
We thank the Journal for the opportunity to present an addendum to our article,‘‘Assessing the Reproducibility of Asthma Candidate Gene Associations using Genome-wide Data’’(1). In that work, we studied 39 replicated asthma gene regions using data from the Illumina 550kv3 genome-wide SNP genotyping platform. We reported the results of SNP-level replication within 6 genes and additional ‘‘gene-level’’replication in 15 more genes. Lima and colleagues reported that the gene encoding atrial natriuretic peptide, NPPA, was associated with asthma in two populations (2), and thus their results were included in our study. We assessed 6 SNPs in NPPA, including one SNP (rs5065) which was directly tested by Lima and coworkers (2). We found evidence of association in 3 SNPs in NPPA (twosided P, 0.05); in all cases transmission of the minor allele conferred a decreased risk of asthma. We incorrectly reported that our association in rs5065 was in the opposite direction of that identified by Lima and coworkers. In fact, the minor allele for marker rs5065 (G on the 1 strand) was associated with decreased asthma susceptibility in both the original publication by Lima and coworkers (2) and in our study (1). Thus, our replication of the association between NPPA and asthma is more compelling than we had originally reported.Conflict of Interest Statement: AJR has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. BAR has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. JL has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. JAL has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. AM has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. RL has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. BK has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. JSS has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. JPZ has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. CL has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. JCC has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. EKS received an honorarium for a talk on COPD genetics in 2006, grant support for two studies of COPD genetics (2004–2009), and consulting fees (2005–2009) from GlaxoSmithKline; he received an honorarium from Wyeth for a talk on COPD genetics in 2004; he received an honorarium from Bayer for a symposium at the ERS Meeting in 2005; and he received honoraria for talks in 2007 and 2008 and consulting fees in 2008–2009 from AstraZeneca. STW was a grant recipient and consultant for Glaxo-Wellcome (2000–2005); a grant recipient for AstraZeneca (1997–2003); a consultant to the TENOR Study for Genentech, receiving $20,000 over 2007 and 2008; a grant recipient for Pfizer (2000–2003); and a consultant for Schering-Plough (1999-2000, 2009-present), Variagenics (2002), Millennium Pharmaceuticals (1996–2001), Genome Therapeutics (2003), Roche Pharmaceuticals (2000–2002), and Merck Frost (2002).
